EuroBiotech Report—Bavarian Nordic, Nabriva, Immunocore, Glythera-Iontas and Sanofi


Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with the mixed late-phase fortunes of two European biotechs. The bad news hit Bavarian Nordic, which saw its share price drop 50% after a phase 3 trial of its Bristol-Myers Squibb-partnered prostate cancer vaccine was stopped early for futility. Nabriva Therapeutics had better news. The share price of the Austrian-born biotech doubled on the back of phase 3 data showing its antibiotic lefamulin held its own against the incumbent product. U.K. cancer biotech Immunocore furthered its move into infectious diseases by landing a $40 million investment from the Bill & Melinda Gates Foundation. Glythera teamed up with Iontas to access a source of antibodies. Sanofi reported an early success in HIV. And more. —Nick Taylor  

1. Bavarian Nordic tanks after Bristol-Myers-partnered vaccine flunks phase 3

Bavarian Nordic’s repeatedly delayed phase 3 cancer vaccine trial has come crashing to a halt. The data monitoring committee ended the six-year odyssey after ruling it would be futile to keep treating patients with the Bristol-Myers Squibb-partnered Prostvac.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

2. Phase 3 antibiotic win sends Nabriva stock into overdrive

A phase 3 trial of Nabriva Therapeutics’ antibiotic lefamulin has met its primary endpoint. The drug held its own against established treatment moxifloxacin, raising hopes that Nabriva can establish it as a first-line monotherapy treatment of community-acquired bacterial pneumonia (CABP).

3. Gates invests in Immunocore to spur infectious disease R&D

The Bill & Melinda Gates Foundation is investing up to $40 million in Immunocore to spur research into the use of T cell receptor (TCR)-based therapeutics to treat tuberculosis and HIV.

4. Glythera taps Iontas for antibodies to guide next-generation ADCs

Glythera has struck a deal to access a source of antibodies against specified targets. Iontas will use its phage display libraries and other antibody discovery capabilities to provide Glythera with a key component of its planned antibody-drug conjugates (ADCs).

5. Sanofi and NIH chart early success with 3-part antibody against HIV

Researchers announced that their trispecific antibody protected monkeys against SHIV, a similar virus, and that it outperformed the individual antibodies from which their engineered compound originated.

And more articles of note >>

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.